The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Interactions Between the Intestinal Microbiome and Liver Diseases
Open accessAbstract
The human intestine harbors a diverse community of microbes that promote metabolism and digestion in their symbiotic relationship with the host. Disturbance of its homeostasis can result in disease. We review factors that disrupt intestinal homeostasis and contribute to nonalcoholic fatty liver disease, steatohepatitis, alcoholic liver disease, and cirrhosis. Liver disease has long been associated with qualitative and quantitative (overgrowth) dysbiotic changes in the intestinal microbiota. Extrinsic factors, such as the Western diet and alcohol, contribute to these changes. Dysbiosis results in intestinal inflammation, a breakdown of the intestinal barrier, and translocation of microbial products in animal models. However, the contribution of the intestinal microbiome to liver disease goes beyond simple translocation of bacterial products that promote hepatic injury and inflammation. Microbial metabolites produced in a dysbiotic intestinal environment and host factors are equally important in the pathogenesis of liver disease. We review how the combination of liver insult and disruptions in intestinal homeostasis contribute to liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the impact of changes to the composition and function of the microbiome in NASH include altered bile acid metabolism and loss of integrity of the gut-vascular barrier, precipitating leakage of LPS and bacteria into the liver via the portal circulation (14–16).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“Changes in gut microbiota (dysbiosis) may play a key role in the pathogenesis of NAFLD/NASH and cholestasis52–54 and may also impact on BA composition and signalling.51 55”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [54]
In the citing paper
“However, a failing gut barrier and alterations of the gut microbiota in chronic liver disease (CLD) contribute to chronic inflammation and the progression of liver diseases12, and thereby increase risk for the development of hepatocellular carcinoma (HCC) as the final stage of the disease process 13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [12]
In the citing paper
“Metagenomic studies have revealed substantial alterations in the composition of the gut microbiota in a range of CLD as well as in patients with cirrhosis12,32.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Linking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Intestinal mucosal barrier function in health and disease
Turner, J. R. (2009) · Nature reviews. Immunology · doi:10.1038/nri2653 · Cited by 3,952
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615
Cited by
Sorted by citations
Items 201–300 of 974
Saikia, P., Bellos, D., McMullen, M. R., Pollard, K. A., de la Motte, C., & Nagy, L. E. (2017) · Hepatology · doi:10.1002/hep.29144 · Cited by 81
Hepatic Stellate Cell-Immune Interactions in NASH
Carter, J. K., & Friedman, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.867940 · Cited by 79
Zearalenone disturbs the reproductive-immune axis in pigs: the role of gut microbial metabolites
Wang, S., Fu, W., Zhao, X., Chang, X., Liu, H., Zhou, L., Li, J., Cheng, R., Wu, X., Li, X., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01397-7 · Cited by 80
Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism
Liu, J., Sun, J., Yu, J., Chen, H., Zhang, D., Zhang, T., Ma, Y., Zou, C., Zhang, Z., Ma, L., et al. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00399-z · Cited by 88
Alcohol metabolism and oesophageal cancer: a systematic review of the evidence
Matejcic, M., Gunter, M. J., & Ferrari, P. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx067 · Cited by 80
Candida albicans and candidalysin in inflammatory disorders and cancer
Ho, J., Camilli, G., Griffiths, J. S., Richardson, J. P., Kichik, N., & Naglik, J. R. (2020) · Immunology · doi:10.1111/imm.13255 · Cited by 82
Relationship between intestinal microbial dysbiosis and primary liver cancer
Zhang, L., Wu, Y.-N., Chen, T., Ren, C.-H., Li, X., & Liu, G. (2019) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2019.01.002 · Cited by 80
Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD
Jiang, X., Zheng, J., Zhang, S., Wang, B., Wu, C., & Guo, X. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00361 · Cited by 80
Immunoglobulin A and liver diseases
Inamine, T., & Schnabl, B. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1400-8 · Cited by 76
Self-citationEffect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease
Jung, Y., Kim, I., Mannaa, M., Kim, J., Wang, S., Park, I., Kim, J., & Seo, Y. (2018) · Food Science and Biotechnology · doi:10.1007/s10068-018-0433-y · Cited by 79
TaxoNN: ensemble of neural networks on stratified microbiome data for disease prediction
Sharma, D., Paterson, A. D., & Xu, W. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa542 · Cited by 76
Xi, Y., Yan, J., Li, M., Ying, S., & Shi, Z. (2019) · Poultry Science · doi:10.3382/ps/pez357 · Cited by 76
Fianchi, F., Liguori, A., Gasbarrini, A., Grieco, A., & Miele, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126485 · Cited by 77
Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either
Hartmann, P., Chu, H., Duan, Y., & Schnabl, B. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00370.2018 · Cited by 74
Self-citationProtective Effects of Ellagic Acid Against Alcoholic Liver Disease in Mice
Zhao, L., Mehmood, A., Soliman, M. M., Iftikhar, A., Iftikhar, M., Aboelenin, S. M., & Wang, C. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.744520 · Cited by 74
The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis
Zhang, Y., Li, Z.-J., Gou, H.-Z., Song, X., & Zhang, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.945368 · Cited by 77
Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis
Louvet, A., Labreuche, J., Dao, T., Thévenot, T., Oberti, F., Bureau, C., Paupard, T., Nguyen-Khac, É., Minello, A., Bernard‐Chabert, B., et al. (2023) · JAMA · doi:10.1001/jama.2023.4902 · Cited by 74
Videnska, P., Šmerková, K., Zwinsova, B., Popovici, V. C., Micenková, L., Sedlář, K., & Budínská, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-49520-3 · Cited by 77
Chen, J., Xuan, Y.-H., Luo, M.-X., Ni, X.-G., Ling, L.-Q., Hu, S.-J., Chen, J.-Q., Xu, J., Jiang, L., Si, W.-Z., et al. (2019) · Toxicology · doi:10.1016/j.tox.2019.152338 · Cited by 71
Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis
Wang, F.-D., Zhou, J., & Chen, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.787748 · Cited by 79
Chen, J., Wei, Y., He, J., Cui, G., Zhu, Y., Lu, C., Ding, Y., Xue, R., Bai, L., Uede, T., et al. (2014) · Scientific Reports · doi:10.1038/srep07259 · Cited by 71
Gut microbiota and non-alcoholic fatty liver disease
Gkolfakis, P., Dimitriadis, G., & Τriantafyllou, Κ. (2015) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(15)60026-1 · Cited by 80
Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature
Mohammed, H., Varoni, E. M., Cochis, A., Cordaro, M., Gallenzi, P., Patini, R., Staderini, E., Lajolo, C., Rimondini, L., & Rocchetti, V. (2018) · Biomedicines · doi:10.3390/biomedicines6040115 · Cited by 71
Costa, M. A. D. C., Vilela, D. L. D. S., Fraiz, G. M., Lopes, I. L., Coelho, A. Í. M., Castro, L. C. V., & Martin, J. G. P. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1995321 · Cited by 85
Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?
Portincasa, P., Khalil, M., Graziani, A., Frühbeck, G., Baffy, G., Garruti, G., Ciaula, A. D., & Bonfrate, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.002 · Cited by 78
Gong, S., Ye, T., Wang, M., Wang, M., Li, Y., Ma, L., Yang, Y., Wang, Y., Zhao, X., Liu, L., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00297 · Cited by 72
Bilberry Anthocyanins Ameliorate NAFLD by Improving Dyslipidemia and Gut Microbiome Dysbiosis
Nakano, H., Wu, S., Sakao, K., Hara, T., He, J., García, S., Shetty, K., & Hou, D. (2020) · Nutrients · doi:10.3390/nu12113252 · Cited by 74
Alcoholic and non-alcoholic steatohepatitis
Neuman, M. G., French, S. W., French, B. A., Seitz, H. K., Cohen, L. B., Mueller, S., Osna, N. A., Kharbanda, K. K., Seth, D., Bautista, A. P., et al. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.09.005 · Cited by 73
Gut Microbiota and Chemical-Induced Acute Liver Injury
Chen, T., Li, R., & Chen, P. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.688780 · Cited by 71
Qian, M., Liu, J., Zhao, D., Cai, P., Pan, C., Jia, W., Gao, Y., Zhang, Y., Zhang, N., Zhang, Y., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.08.014 · Cited by 71
Self-citationExercise and diet in the management of nonalcoholic fatty liver disease
Mahady, S. E., & George, J. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.032 · Cited by 73
Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver
Lutz, P. L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.304 · Cited by 67
Zhang, R., Pan, Z., Wang, X., Shen, M., Zhou, J., Fu, Z., & Jin, Y. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy153 · Cited by 67
Publisher Correction: The gut–liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0031-8 · Cited by 70
Self-citationRainer, F., Horvath, A., Sandahl, T. D., Leber, B., Schmerboeck, B., Blesl, A., Groselj‐Strele, A., Stauber, R. E., Fickert, P., Stiegler, P., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14474 · Cited by 65
Mechanisms of sepsis-induced acute liver injury: a comprehensive review
Guo, Y., Guo, W., Chen, H., Sun, J., & Yin, Y. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1504223 · Cited by 73
Bile acids and cardiovascular function in cirrhosis
Voiosu, A. M., Wiese, S. S., Voiosu, T. A., Bendtsen, F., & Møller, S. (2017) · Liver International · doi:10.1111/liv.13394 · Cited by 70
Borém, L. M. A., Neto, J. F. R., Brandi, I. V., Lelis, D. D. F., & Santos, S. H. S. (2018) · Hypertension Research · doi:10.1038/s41440-018-0040-6 · Cited by 70
Wijarnpreecha, K., Lou, S. M., Watthanasuntorn, K., Kröner, P. T., Cheungpasitporn, W., Lukens, F., Pungpapong, S., Keaveny, A. P., & Ungprasert, P. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001541 · Cited by 65
Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?
Jiang, L., & Schnabl, B. (2020) · Physiology · doi:10.1152/physiol.00005.2020 · Cited by 64
Self-citationGustot, T., Stadlbauer, V., Laleman, W., Alessandria, C., & Thursz, M. R. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.005 · Cited by 76
Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma
Shen, R. D., Ke, L., Li, Q., Dang, X., Shen, S., Shen, J., Li, S., Liang, L., Peng, B., Kuang, M., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10299-7 · Cited by 67
Gut Microbiota and Host Reaction in Liver Diseases
Fukui, H. (2015) · Microorganisms · doi:10.3390/microorganisms3040759 · Cited by 64
Tian, F., Chi, F., Wang, G., Liu, X., Zhang, Q., Chen, Y. Q., Zhang, H., & Chen, W. (2015) · The Journal of Microbiology · doi:10.1007/s12275-015-5239-5 · Cited by 65
Celiac Disease and Liver Disorders: From Putative Pathogenesis to Clinical Implications
Hoffmanová, I., Sánchez, D., Tučková, L., & Tlaskalová‐Hogenová, H. (2018) · Nutrients · doi:10.3390/nu10070892 · Cited by 65
TRIF differentially regulates hepatic steatosis and inflammation/fibrosis in mice
Yang, L., Miura, K., Zhang, B., Matsushita, H., Yang, Y. M., Liang, S., Song, J., Roh, Y. S., & Seki, E. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.12.004 · Cited by 62
Liver as a target of human immunodeficiency virus infection
Ganesan, M., Poluektova, L. Y., Kharbanda, K. K., & Osna, N. A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i42.4728 · Cited by 67
Yang, X., Zheng, M., Zhou, M., Zhou, L., Ge, X., Pang, N., Li, H., Li, X., Li, M., Zhang, J., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.803691 · Cited by 64
Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders
Lim, S. K., Oh, T. J., & Koh, K. K. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.107 · Cited by 64
The potential of silymarin for the treatment of hepatic disorders
Hellerbrand, C., Schattenberg, J. M., Peterburs, P., Lechner, A., & Brignoli, R. (2016) · Clinical Phytoscience · doi:10.1186/s40816-016-0019-2 · Cited by 67
Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases
Yang, T., Khan, G. J., Wu, Z., Wang, X., Zhang, L., & Jiang, Z. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.007 · Cited by 65
Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease
Grattagliano, I., Montezinho, L. P., Oliveira, P. J., Frühbeck, G., Gómez‐Ambrosi, J., Montecucco, F., Carbone, F., Wieckowski, M. R., Wang, D. Q. ‐., & Portincasa, P. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.020 · Cited by 66
Zhao, H., Luo, Y., Wu, Z., Zhou, Y., Guo, D., Wang, H., & Chen, X. (2019) · Aquaculture · doi:10.1016/j.aquaculture.2019.05.029 · Cited by 63
Huang, H., Wang, Q., Yang, Y., Zhong, W., He, F., & Li, . (2024) · Gut Microbes · doi:10.1080/19490976.2024.2440111 · Cited by 74
Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease
Aragonès, G., González-García, S., Aguilar, C., Richart, C., & Auguet, T. (2019) · BioMed Research International · doi:10.1155/2019/8507583 · Cited by 69
Nistal, E., de Miera, L. E. S., Ballesteros-Pomar, M. D., Sánchez‐Campos, S., García‐Mediavilla, M. V., Álvarez-Cuenllas, B., Linares, P., Olcoz, J. L., Arias, M., Lobo, J. M. G., et al. (2019) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2019.6068/2018 · Cited by 64
Qian, M., Lyu, Q., Liu, Y., Hu, H., Wang, S., Pan, C., Duan, X., Gao, Y., Qi, L., Liu, W., et al. (2019) · Marine Drugs · doi:10.3390/md17070391 · Cited by 63
Zhang, Y., Zhao, F., Deng, Y., Zhao, Y., & Ren, H. (2015) · Journal of Proteome Research · doi:10.1021/pr5011263 · Cited by 62
Prokopidis, K., & Witard, O. C. (2021) · Nutrition Research Reviews · doi:10.1017/s0954422421000135 · Cited by 66
Guo, W., Cao, Y.-J., You, S.-Z., Wu, Q., Zhang, F., Han, J., Lv, X., Rao, P., Ai, L., & Ni, L. (2022) · Current Research in Food Science · doi:10.1016/j.crfs.2022.02.013 · Cited by 62
Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease
Wang, C., Zhu, C., Shao, L., Ye, J., Shen, Y., & Ren, Y. (2019) · Mediators of Inflammation · doi:10.1155/2019/7659509 · Cited by 67
Pathogenesis and Management of Alcoholic Liver Disease
Farooq, M. O., & Bataller, R. A. (2016) · Digestive Diseases · doi:10.1159/000444545 · Cited by 61
CEACAM1 in Liver Injury, Metabolic and Immune Regulation
Horst, A. K., Najjar, S. M., Wagener, C., & Tiegs, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103110 · Cited by 63
Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis
Schneider, K. M., Mohs, A., Kilic, K., Candels, L. S., Elfers, C., Bennek, E., Schneider, L. B., Heymann, F., Gaßler, N., Penders, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020308 · Cited by 61
Modulation of bile acid profile by gut microbiota in chronic hepatitis B
Wang, X., Chen, L., Wang, H., Cai, W., & Xie, Q. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14951 · Cited by 65
Moghadamrad, S., McCoy, K. D., Geuking, M. B., Sägesser, H., Kirundi, J., Macpherson, A. J., & Gottardi, A. D. (2015) · Hepatology · doi:10.1002/hep.27698 · Cited by 60
Ursolic Acid Improves Intestinal Damage and Bacterial Dysbiosis in Liver Fibrosis Mice
Wan, S., Liu, C., Huang, C., Luo, F., & Zhu, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01321 · Cited by 60
Yin, J., Ren, W., Wei, B., Huang, H., Li, M., Wu, X., Wang, A., Xiao, Z., Shen, J., Zhao, Y., et al. (2020) · Food Chemistry · doi:10.1016/j.foodchem.2020.126568 · Cited by 57
Host miRNA-21 promotes liver dysfunction by targeting small intestinal Lactobacillus in mice
Santos, A. A., Afonso, M. B., Ramiro, R. S., Pires, D., Pimentel, M., Castro, R. E., & Rodrigues, C. M. P. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1840766 · Cited by 63
Microbiome: A forgotten target of environmental micro(nano)plastics?
Santos, A. L., Rodrigues, C. C., Oliveira, M., & Rocha, T. L. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.153628 · Cited by 61
Are We What We Eat? Impact of Diet on the Gut–Brain Axis in Parkinson’s Disease
Alfonsetti, M., Castelli, V., & d’Angelo, M. (2022) · Nutrients · doi:10.3390/nu14020380 · Cited by 61
Potential mechanisms linking gut microbiota and portal hypertension
Baffy, G. (2018) · Liver International · doi:10.1111/liv.13986 · Cited by 59
Zhao, Y., Duan, C., Zhang, X., Chen, H., Ren, H., Yin, Y., & Ye, L. (2018) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1709.09070 · Cited by 58
Wolstenholme, J. T., Saunders, J. M., Smith, M. L., Kang, J. D., Hylemon, P. B., González‐Maeso, J., Fagan, A., Zhao, D., Sikaroodi, M., Herzog, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34054-6 · Cited by 60
Wu, J., Shao, H., Zhang, J., Ying, Y., Cheng, Y., Zhao, D., Dou, X., Lv, H., Li, S., Liu, F., et al. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.02.097 · Cited by 57
Lin, S., Zhang, T., Zhu, L., Pang, K., Lu, S., Liao, X., Ying, S., Zhu, L., Xu, X., Wu, J., et al. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.06.009 · Cited by 57
Tian, X., Li, R., Jiang, Y., Zhao, F., Yu, Z., Wang, Y., Dong, Z., Liu, P., & Li, X. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104045 · Cited by 55
Yang, Y., Li, M., Wang, Q., Huang, H., Zhao, Y., Du, F., Chen, Y., Shen, J., Luo, H., Zhao, Q., et al. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111401 · Cited by 54
Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity
Hartmann, P., Seebauer, C. T., Mazagova, M., Horvath, A., Wang, L., Llorente, C., Varki, N. M., Brandl, K., Ho, S. B., & Schnabl, B. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00094.2015 · Cited by 56
Self-citationRemote Sensing Between Liver and Intestine: Importance of Microbial Metabolites
Fu, Z. D., & Cui, J. Y. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0087-0 · Cited by 54
Jaworska, K., Konop, M., Hutsch, T., Perlejewski, K., Radkowski, M., Grochowska, M., Bielak-Żmijewska, A., Mosieniak, G., Sikora, E., & Ufnal, M. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz181 · Cited by 53
Carter, J. K., Bhattacharya, D., Borgerding, J. N., Fiel, M. I., Faith, J. J., & Friedman, S. L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0244763 · Cited by 52
Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.
Bieghs, V., & Trautwein, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2014.12.04 · Cited by 54
Role of the intestinal microbiome in liver fibrosis development and new treatment strategies
Zhou, R., Fan, X., & Schnabl, B. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.005 · Cited by 53
Self-citationCornide‐Petronio, M. E., Álvarez‐Mercado, A. I., Jiménez‐Castro, M. B., & Peralta, C. (2020) · Nutrients · doi:10.3390/nu12020284 · Cited by 52
The Immune System through the Lens of Alcohol Intake and Gut Microbiota
Calleja‐Conde, J., Echeverry‐Alzate, V., Bühler, K., Durán‐González, P., Morales-Garcia, J. A., Segovia‐Rodríguez, L., de Fonseca, F. R., Giné, E., & López‐Moreno, J. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147485 · Cited by 75
Choi, K. J., Yoon, M. Y., Kim, J.-E., & Yoon, S. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-41160-y · Cited by 51
Ghoshal, U. C., Baba, C. S., Ghoshal, U., Alexander, G., Misra, A., Saraswat, V. A., & Choudhuri, G. (2017) · Indian Journal of Gastroenterology · doi:10.1007/s12664-017-0797-6 · Cited by 53
Song, L., Li, Y., Qu, D. C., Ouyang, P.-L., Ding, X., Wu, P., Guan, Q., & Yang, L. (2019) · Food & Function · doi:10.1039/c9fo01570a · Cited by 53
Miao, R., Badger, T. C., Groesch, K. A., Díaz‐Sylvester, P., Wilson, T. S., Ghareeb, A. A., Martin, J. A., Cregger, M. A., Welge, M. E., Bushell, C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227707 · Cited by 51
Oral microbial community analysis of the patients in the progression of liver cancer
Li, D., Xi, W., Zhang, Z., Ren, L., Deng, C., Chen, J., Sun, C., Zhang, N., & Xu, J. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104479 · Cited by 52
Liu, Y., Li, J., Jin, Y., Zhao, L., Zhao, F., Feng, J., Li, A., & Wei, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00963 · Cited by 51
Protective Role of Probiotic Supplements in Hepatic Steatosis: A Rat Model Study
Azarang, A., Farshad, O., Ommati, M. M., Jamshidzadeh, A., Heidari, R., Abootalebi, S. N., & Gholami, A. (2020) · BioMed Research International · doi:10.1155/2020/5487659 · Cited by 51
Nevens, F., Trauner, M., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 51
Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis
Hammerich, L., & Tacke, F. (2015) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v6.i3.43 · Cited by 50
Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning?
Baran, B. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14219 · Cited by 51
He, J.-J., Ma, J., Elsheikha, H. M., Song, H., Huang, S., & Zhu, X.-Q. (2016) · Parasites & Vectors · doi:10.1186/s13071-016-1716-x · Cited by 50
Old and new treatments for primary biliary cholangitis
Chascsa, D. M. H., Carey, E. J., & Lindor, K. D. (2017) · Liver International · doi:10.1111/liv.13294 · Cited by 50
Zhu, Y., Wang, X., Zhu, L., Tu, Y., Chen, W., Gong, L., Pan, T., Lin, H., Lin, J., Sun, H., et al. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115923 · Cited by 49
An update on the pathogenesis and clinical management of cirrhosis with refractory ascites
Neong, S. F., Adebayo, D., & Wong, F. S.-H. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1555469 · Cited by 49
Metadata
- Authors
- Schnabl, B., & Brenner, D. A.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Schnabl, Bernd
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 146
- Issue
- 6
- Pages
- 1513-1524
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC3996054
- OpenAlex
- W1975691929
- Cited by
- 971
- References
- 86
- Citations by year
- 2026: 37 · 2025: 56 · 2024: 88 · 2023: 101 · 2022: 88 · 2021: 92 · 2020: 102 · 2019: 88 · 2018: 89 · 2017: 58 · 2016: 64 · 2015: 77 · 2014: 31
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (U01 AA021856, R01 AA020703, 2 P42 ES010337, K08 DK081830)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- gut microbiota, gut-liver axis, non-alcoholic fatty liver disease, steatohepatitis, alcoholic liver disease, liver cirrhosis, dysbiosis, intestinal homeostasis, intestinal barrier dysfunction, intestinal inflammation, microbial translocation, microbial metabolites, Western diet, alcohol
- MeSH terms
- Animals, Bacteria, Bile Acids and Salts, Fatty Liver, Humans, Intestines, Liver Cirrhosis, Liver Diseases, Liver Diseases, Alcoholic, Risk Factors, Host-Pathogen Interactions, Microbiota, Dysbiosis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
